Novo's Ozempic® (Semaglutide) 2 MG Associated With Lower Risk Of Major Adverse Cardiovascular Events (Death
Novo's Ozempic® (Semaglutide) 2 MG Associated With Lower Risk Of Major Adverse Cardiovascular Events (Death
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Real-world study links Ozempic 2 mg with lower MACE vs Mounjaro
Novo’s Ozempic (semaglutide) 2 mg was associated with a lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro (tirzepatide), in real-world analysis at EASD.